ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

disitamab vedotin

Also written as “RC48-ADC”, “Disitamab Vedotin” and “Disitamab Vedotin Injection”.

In Pfizer’s pipeline, HER2-directed antibody-drug conjugate. Its studies are mostly in Stomach Neoplasms · Breast Neoplasms · Carcinoma, Transitional Cell · Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms, led by 3 companies.

Drug pageDisitamab vedotin: every studyAll 117 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 8, 201836 company-led studies, 28 open or runningAcquisition: Pfizer acquired Seagen, Dec 2023Next primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGenits history only3022 open or runningphase 3since Apr 8, 2018Aug 20, 2016Dec 2026phase 3 · NCT06221748
Pfizer55 open or runningphase 3since Jun 9, 2023Apr 19, 2021Dec 11, 2026phase 2 · NCT04879329
Jiangsu HengRui Medicineits history only11 open or runningphase 2since Apr 26, 2024Apr 26, 2024Dec 31, 2031phase 2 · NCT06417554
  • Named in Pfizer’s own pipeline as disitamab vedotin PF-08046051, phase 3, as of Nov 3, 2026 (source).

Also a collaborator on its studies: Merck.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Jiangsu HengRui Medicine relates to it is not in the registry or these sources.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2018Named disitamab vedotinINNProposed as its International Nonproprietary Name in WHO's List 120
  2. Apr 19, 2021First study: phase 2 study in Carcinoma, Transitional CellFirst studyNCT04879329 · 372 planned · United States, Argentina, Australia and more
  3. Aug 9, 2021Seagen licensed it from RemeGenLicenseEverywhere outside Asia, and in Japan and Singapore · announced · Seagen and RemeGen (release)
  4. Jun 9, 2023Phase 3 study in Carcinoma, Transitional CellNCT05911295 · 412 enrolled · United States, Argentina, Australia and more
  5. Aug 15, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06003231 · 120 enrolled · United States, Australia, Canada and more
  6. Nov 27, 2023Phase 2 study in Breast NeoplasmsNCT06157892 · 54 enrolled · United States, Australia, Canada and more
  7. Dec 14, 2023Pfizer acquired SeagenAcquisitionWith it the rights Seagen held · completed · Pfizer (release)
  8. May 9, 2025Phase 2 study in Breast NeoplasmsNCT06966453 · 74 enrolled · United States, Australia, Brazil and more

Ahead

  1. Dec 11, 2026Primary completion: phase 2 study in Carcinoma, Transitional CellNCT04879329
  2. Jan 29, 2027Primary completion: phase 3 study in Carcinoma, Transitional CellNCT05911295
  3. Oct 25, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06966453
  4. Jul 28, 2029Primary completion: phase 2 study in Breast NeoplasmsNCT06157892

TargetBeta

“HER2-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of disitamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated, via the protease-cleavable linker maleimidocaproyl-valine-…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of disitamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 5 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06966453Breast Neoplasms · United States, Australia, Brazil and more2Active, not recruitingOct 25, 202774
NCT06157892Breast Neoplasms · United States, Australia, Canada and more2Active, not recruitingJul 28, 202954
NCT06003231Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2Active, not recruitingMar 27, 2026120
NCT05911295Carcinoma, Transitional Cell · United States, Argentina, Australia and more3Active, not recruitingJan 29, 2027412
NCT04879329Carcinoma, Transitional Cell · United States, Argentina, Australia and more2RecruitingDec 11, 2026372

How it is read

Names in the registry

  • “RC48-ADC”, 15 entries
  • “disitamab vedotin”, 4 entries
  • “Disitamab Vedotin”, 3 entries
  • “Disitamab Vedotin Injection”, 3 entries
  • “Disitamab vedotin”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.